BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34324220)

  • 1. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.
    Karmali R; Switchenko JM; Goyal S; Shanmugasundaram K; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK; Gordon MJ; Danilov AV; Grover NS; Epperla N; Mathews S; Burkart M; Sawalha Y; Hill BT; Ghosh N; Park SI; Bond DA; Maddocks KJ; Badar T; Fenske TS; Hamadani M; Guo J; Malecek M; Kahl BS; Martin P; Blum KA; Flowers CR; Cohen JB
    Am J Hematol; 2021 Nov; 96(11):1374-1384. PubMed ID: 34324220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients].
    Campbell J; Hurtado S; Kutz C; Soto K; Ernst D
    Rev Med Chil; 2019; 147(1):9-17. PubMed ID: 30848759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
    Gerson JN; Handorf E; Villa D; Gerrie AS; Chapani P; Li S; Medeiros LJ; Wang MI; Cohen JB; Calzada O; Churnetski MC; Hill BT; Sawalha Y; Hernandez-Ilizaliturri FJ; Kothari S; Vose JM; Bast MA; Fenske TS; Narayana Rao Gari S; Maddocks KJ; Bond D; Bachanova V; Kolla B; Chavez J; Shah B; Lansigan F; Burns TF; Donovan AM; Wagner-Johnston N; Messmer M; Mehta A; Anderson JK; Reddy N; Kovach AE; Landsburg DJ; Glenn M; Inwards DJ; Karmali R; Kaplan JB; Caimi PF; Rajguru S; Evens A; Klein A; Umyarova E; Pulluri B; Amengual JE; Lue JK; Diefenbach C; Fisher RI; Barta SK
    J Clin Oncol; 2019 Feb; 37(6):471-480. PubMed ID: 30615550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
    Chang JE; Carmichael LL; Kim K; Peterson C; Yang DT; Traynor AM; Werndli JE; Huie MS; McFarland TA; Volk M; Blank J; Callander NS; Longo WL; Kahl BS
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e61-e67. PubMed ID: 29191715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
    Rampotas A; Wilson MR; Lomas O; Denny N; Leary H; Ferguson G; McKay P; Ebsworth T; Miller J; Shah N; Martinez-Calle N; Bishton M; Everden A; Tucker D; El-Hassad E; Hennessy B; Doherty D; Prideaux S; Faryal R; Hayat A; Keohane C; Marr H; Gibb A; Pocock R; Lambert J; Lacey R; Elmusharaf N; Clifford R; Eyre TA
    Br J Haematol; 2021 Jul; 194(2):365-377. PubMed ID: 33959947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population.
    Yang X; Khoo LP; Chang EWY; Yang VS; Poon E; Somasundaram N; Farid M; Tang TPL; Tao M; Lim ST; Chan JY
    BMC Cancer; 2021 May; 21(1):566. PubMed ID: 34001056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis.
    Yang P; Cai QQ; Zhang W; Liu SZ; Liu H; Sun XH; Dong YJ; Xiao XB; Wang JW; Li ZL; Huang WR; Li LH; Bao HZ; Yang W; Wang YL; Wang SY; He J; Li XL; Liu AC; Jing HM
    Cancer Med; 2023 Jun; 12(12):13204-13216. PubMed ID: 37148540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.
    He JS; Chen X; Wei GQ; Sun J; Zheng WY; Shi JM; Wu WJ; Zhao Y; Zheng GF; Huang H; Cai Z
    Medicine (Baltimore); 2019 Jan; 98(1):e13741. PubMed ID: 30608386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry
    Obr A; Prochazka V; Papajik T; Klener P; Janikova A; Salek D; Belada D; Pytlík R; Sykorova A; Mocikova H; Simkovic M; Campr V; Dlouha J; Furst T; Trněný M
    Leuk Lymphoma; 2019 Mar; 60(3):748-755. PubMed ID: 30188225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.
    Mei MG; Cao TM; Chen L; Song JY; Siddiqi T; Cai JL; Farol LT; Al Malki MM; Salhotra A; Aldoss I; Palmer J; Herrera AF; Zain J; Popplewell LL; Chen RW; Rosen ST; Forman SJ; Kwak L; Nademanee AP; Budde LE
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1861-1869. PubMed ID: 28733266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.
    Ruan J; Martin P; Christos P; Cerchietti L; Tam W; Shah B; Schuster SJ; Rodriguez A; Hyman D; Calvo-Vidal MN; Smith SM; Svoboda J; Furman RR; Coleman M; Leonard JP
    Blood; 2018 Nov; 132(19):2016-2025. PubMed ID: 30181173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma.
    Liu P; Han Y; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Zhou LQ; Yang JL; Yang S; Wen TY; Shi YK
    Chin Med J (Engl); 2019 Aug; 132(15):1807-1814. PubMed ID: 31335477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma.
    Villa D; Sehn LH; Savage KJ; Toze CL; Song K; den Brok WD; Freeman CL; Scott DW; Gerrie AS
    Blood Adv; 2020 Aug; 4(15):3486-3494. PubMed ID: 32735654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
    Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
    Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
    Fayad L; Thomas D; Romaguera J
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S57-62. PubMed ID: 18284717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
    Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
    Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study.
    Morrison VA; Shou Y; Bell JA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Eaddy M; Galaznik A
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e172-e183. PubMed ID: 30691994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL.
    Tisi MC; Moia R; Patti C; Evangelista A; Ferrero S; Spina M; Tani M; Botto B; Celli M; Puccini B; Cencini E; Di Rocco A; Chini C; Ghiggi C; Zambello R; Zanni M; Sciarra R; Bruna R; Ferrante M; Pileri SA; Quaglia FM; Stelitano C; Re A; Volpetti S; Zilioli VR; Arcari A; Merli F; Visco C
    Blood Adv; 2023 Aug; 7(15):3916-3924. PubMed ID: 37171620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era.
    Mussetti A; Devlin SM; Castro-Malaspina HR; Barker JN; Giralt SA; Zelenetz AD; Sauter CS; Perales MA
    Bone Marrow Transplant; 2015 Oct; 50(10):1293-1298. PubMed ID: 26146802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.
    Chen RW; Palmer JM; Tomassetti S; Popplewell LL; Alluin J; Chomchan P; Nademanee AP; Siddiqi T; Tsai NC; Chen L; Zuo F; Abary R; Cai JL; Herrera AF; Rossi JJ; Rosen ST; Forman SJ; Kwak LW; Holmberg LA
    J Hematol Oncol; 2018 Jun; 11(1):87. PubMed ID: 29954415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.